Test Price
2,800 AED✅ Home Collection Available
CST3 Gene Cerebral Amyloid Angiopathy Genetic Test – Dubai Healthcare City | DNA Labs UAE
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 accredited next-generation sequencing (NGS) processing at DNA Labs UAE.
Premium Logistics: VIP mobile phlebotomy and temperature-controlled cold-chain home collection available daily from 8 AM to 11 PM across all Emirates.
Clinical Guidance: Post-test telephonic counselling with a consultant medical geneticist to interpret results and outline management pathways.
Insurance: Direct billing verification and pre-authorisation via WhatsApp +971 54 548 8731.
Price: AED 2,800 – inclusive of genetic counselling and DHA-compliant clinical reporting.
Test Overview & Methodology
This targeted next-generation sequencing (NGS) assay analyses the complete coding region and conserved splice sites of the CST3 gene, which encodes the cysteine protease inhibitor cystatin C. Pathogenic variants in CST3 are causally linked to hereditary cerebral amyloid angiopathy (CAA), particularly the Icelandic type (HCHWA-I), characterised by recurrent lobar haemorrhages, cognitive impairment, and progressive white matter disease. Early molecular diagnosis enables tailored surveillance, family cascade testing, and informed reproductive planning.
| Feature | DNA Labs UAE – CST3 NGS Test | Closest Alternative (Single-Gene Sanger) |
|---|---|---|
| Methodology | Illumina NovaSeq X Plus NGS, 100x mean depth, paired-end 150 bp reads | Sanger sequencing of coding exons only |
| Variant Detection | SNVs, indels, CNVs, and deep intronic variants (±20 bp flanking) | Coding SNVs and small indels only |
| Turnaround Time | 21–28 calendar days | 28–42 calendar days |
| Clinical Reporting | ISO 9001:2015 certified, DHA/MOHAP compliant with variant classification per ACMG/AMP guidelines | Standard laboratory report without structured variant interpretation |
| Price (AED) | 2,800 | 3,200–4,000 |
Physician Insight & Safety Protocols
“A CST3 sequence variant of uncertain significance is not a clinical diagnosis; it is a hypothesis that must be contextualised against the patient’s full neurological phenotype, family history, and neuroimaging findings. I advise every patient to review this report during a dedicated session with a consultant medical geneticist and a neurologist. Your clinical story and peace of mind are inseparable from the genomic data.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory – Medication and Clinical Precautions
Never discontinue or alter prescribed antihypertensives, anticonvulsants, or anticoagulant therapy without explicit instruction from your treating physician. Genetic test results do not replace established medical management for stroke risk or seizure control.
Exclusion Criteria and Emergency Red Flags
- Exclusion: Active systemic infection, known bleeding diathesis, or ongoing anticoagulant therapy that cannot be temporarily held per physician order.
- Exclusion: Neonates and children under 2 years without written informed consent from a paediatric neurologist, in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Red Flag: Sudden onset severe headache, focal limb weakness, visual field cut, or loss of consciousness – proceed immediately to the nearest emergency department.
- Red Flag: Unexplained seizure or recurrent stroke-like symptoms warrant urgent MRI/MRA and neurology review, not solely genetic testing.
Patient FAQ & Clinical Guidance
1. What is the CST3 gene and why is this test performed?
The CST3 gene provides instructions for producing cystatin C, a potent inhibitor of cysteine proteases. Pathogenic mutations in this gene cause hereditary cerebral amyloid angiopathy, which predisposes individuals to recurrent haemorrhagic strokes and progressive cognitive decline. This test identifies such mutations to enable early risk stratification, presymptomatic diagnosis, and family-wide counselling.
2. How is the sample collected and can I arrange a home visit?
A trained phlebotomist will visit your home or office with a temperature-controlled cold-chain transport kit. We accept peripheral whole blood (2–5 mL in EDTA), high-quality extracted genomic DNA, or a single dried blood spot on an FTA card. Home collection is available daily from 8 AM to 11 PM across the UAE.
3. What does a pathogenic CST3 variant mean for my health and what steps follow?
A pathogenic variant indicates a significantly elevated lifetime risk of cerebral amyloid angiopathy. Immediate steps include a comprehensive neurological evaluation, brain MRI with susceptibility-weighted imaging, and consultation with a genetic counsellor to discuss cascade testing for at-risk relatives. Lifestyle modifications and blood pressure optimisation are also recommended.
UAE Regulatory & Data Privacy Adherence
Data Protection: All genetic sequence data and personal health information are processed and stored in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
Medical Liability: Patient consent and clinical safety protocols adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability.
Certification: DNA Labs UAE is ISO 9001:2015 certified. All diagnostic reporting follows DHA and MOHAP standards for genetic testing.
Clinical & Logistical Metadata
| Test Name | CST3 Gene Cerebral Amyloid Angiopathy Genetic Test (NGS) |
| Price (AED) | 2,800 |
| Turnaround Time | 21–28 calendar days |
| Sample Type / Matrix | Peripheral whole blood (EDTA), extracted genomic DNA, or FTA card spot; VIP mobile phlebotomy & temperature-controlled cold-chain home collection available daily 8 AM – 11 PM |
| Methodology Used | Next-Generation Sequencing (Illumina NovaSeq X Plus, 100x mean depth, paired-end 150 bp) |
| ICD-10-CM Code | I68.0 – Cerebral amyloid angiopathy |
| LOINC Code | 94218-7 – CST3 gene mutation analysis |
| DHA Facility License & Address | DHA Facility License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians